Merrimack Pharma (MACK) Misses Q1 EPS by 17c

Merrimack Pharma (NASDAQ: MACK) reported Q1 EPS of ($1.33), $0.17 worse than the analyst estimate of ($1.16). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery